TY - JOUR
T1 - Mobilization, harvesting and selection of peripheral blood stem cells in patients with autoimmune diseases undergoing autologous hematopoietic stem cell transplantation
AU - Statkute, L.
AU - Verda, L.
AU - Oyama, Y.
AU - Traynor, A.
AU - Villa, M.
AU - Shook, T.
AU - Clifton, R.
AU - Jovanovic, B.
AU - Satkus, J.
AU - Loh, Y.
AU - Quigley, K.
AU - Yaung, K.
AU - Gonda, E.
AU - Krosnjar, N.
AU - Spahovic, D.
AU - Burt, R. K.
N1 - Funding Information:
We thank the Lupus Foundation of America, Illinois Chapter for their financial and patient support.
PY - 2007/3
Y1 - 2007/3
N2 - Peripheral blood stem cells (PBSC) were mobilized in 130 patients with autoimmune diseases undergoing autologous hematopoietic stem cell transplantation using cyclophosphamide 2g/m2 and either granulocyte colony-stimulating factor (G-CSF) 5mcg/kg/day (for systemic lupus erythematosus (SLE) and secondary progressive multiple sclerosis, SPMS) or G-CSF 10mcg/kg/day (for relapsing remitting multiple sclerosis (RRMS), Crohn's disease (CD), systemic sclerosis (SSc), and other immune-mediated disorders). Mobilization-related mortality was 0.8% (one of 130) secondary to infection. Circulating peripheral blood (PB) CD34+ cells/μl differed significantly by disease. Collected CD34+ cells/kg/apheresis and overall collection efficiency was significantly better using Spectra apheresis device compared to the Fenwall CS3000 instrument. Patients with SLE and RRMS achieved the lowest and the highest CD34+ cell yields, respectively. Ex vivo CD34+ cell selection employing Isolex 300iv2.5 apparatus was significantly more efficient compared to CEPRATE CS device. Circulating PB CD34+ cells/μl correlated positively with initial CD34+ cells/kg/apheresis and enriched product CD34+ cells/kg. Mean WBC and platelet engraftment (ANC > 0.5 × 109/l and platelet count > 20 × 109/l) occurred on days 9 and 11, respectively. Infused CD34+ cell/kg dose showed significant direct correlation with faster white blood cell (WBC) and platelet engraftment. When adjusted for CD34+ cell/kg dose, patients treated with a myeloablative regimen had significantly slower WBC and platelet recovery compared to non-myeloablative regimens.
AB - Peripheral blood stem cells (PBSC) were mobilized in 130 patients with autoimmune diseases undergoing autologous hematopoietic stem cell transplantation using cyclophosphamide 2g/m2 and either granulocyte colony-stimulating factor (G-CSF) 5mcg/kg/day (for systemic lupus erythematosus (SLE) and secondary progressive multiple sclerosis, SPMS) or G-CSF 10mcg/kg/day (for relapsing remitting multiple sclerosis (RRMS), Crohn's disease (CD), systemic sclerosis (SSc), and other immune-mediated disorders). Mobilization-related mortality was 0.8% (one of 130) secondary to infection. Circulating peripheral blood (PB) CD34+ cells/μl differed significantly by disease. Collected CD34+ cells/kg/apheresis and overall collection efficiency was significantly better using Spectra apheresis device compared to the Fenwall CS3000 instrument. Patients with SLE and RRMS achieved the lowest and the highest CD34+ cell yields, respectively. Ex vivo CD34+ cell selection employing Isolex 300iv2.5 apparatus was significantly more efficient compared to CEPRATE CS device. Circulating PB CD34+ cells/μl correlated positively with initial CD34+ cells/kg/apheresis and enriched product CD34+ cells/kg. Mean WBC and platelet engraftment (ANC > 0.5 × 109/l and platelet count > 20 × 109/l) occurred on days 9 and 11, respectively. Infused CD34+ cell/kg dose showed significant direct correlation with faster white blood cell (WBC) and platelet engraftment. When adjusted for CD34+ cell/kg dose, patients treated with a myeloablative regimen had significantly slower WBC and platelet recovery compared to non-myeloablative regimens.
UR - http://www.scopus.com/inward/record.url?scp=33947143592&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33947143592&partnerID=8YFLogxK
U2 - 10.1038/sj.bmt.1705579
DO - 10.1038/sj.bmt.1705579
M3 - Article
C2 - 17277794
AN - SCOPUS:33947143592
SN - 0268-3369
VL - 39
SP - 317
EP - 329
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
IS - 6
ER -